![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lipoxen | LSE:LPX | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.875 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6854N Lipoxen PLC 11 February 2008 Lipoxen PLC ("Lipoxen" or "the Company") Change of Adviser London, UK, 11 February 2008 - Lipoxen PLC (AIM: LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, today announces the appointment of Landsbanki Securities (UK) Limited as Nominated Adviser and Broker to the company with immediate effect. Ends Enquiries: Lipoxen plc +44 (0)20 7691 3583 M. Scott Maguire, Chief Executive Officer Colin Hill, Finance Director Landsbanki Securities (UK) Limited +44 (0)20 7426 9000 Shaun Dobson Claes Spang Citigate Dewe Rogerson +44 (0)20 7638 9571 David Dible Emma Palmer Notes to Editors Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines and oncology drugs. Products currently under development include improved formulations of important biologicals such as EPO, G-CSF, insulin and Interferon-alpha. These novel products which are based on Lipoxen's proprietary PolyXen(R) technology address markets in excess of US$1 billion. This technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen(R) and a related liposomal technology for the formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and InterVet, a leading animal health company. Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006. This information is provided by RNS The company news service from the London Stock Exchange END APPUUUPWPUPRGUB
1 Year Lipoxen Chart |
1 Month Lipoxen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions